Mercy BioAnalytics

Mercy BioAnalytics, Inc. is a Waltham, Massachusetts clinical-stage cancer diagnostics company, founded in 2018, developing extracellular-vesicle (EV) based liquid biopsy tests for the early detection of cancer. Its patented Mercy Halo platform uses biomarker co-localization — the simultaneous detection of multiple cancer-related biomarkers on the surface of individual tumor-derived extracellular vesicles — to read a small volume of serum or plasma with a simple PCR-based readout. The company's initial programs target ovarian cancer screening in asymptomatic post-menopausal women and lung cancer detection in average and high-risk individuals; the Mercy Halo Ovarian Cancer Screening Test received FDA Breakthrough Device Designation in May 2024. Mercy BioAnalytics raised a $41M Series A in April 2023 led by Novalis LifeSciences and a $59M Series B in September 2025. The product is a laboratory-developed blood test, not software: as of this profile the company publishes no public developer program, API, SDK, or machine-readable API contract of any kind.

Mercy BioAnalytics is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Health, Diagnostics, and Biotechnology.

Mercy BioAnalytics’ developer surface includes support and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub

2.9/100 minimal ▬ flat Agent 3/100 human only Full breakdown ↓
scored 2026-09-01 · rubric v0.17.2

0 APIs

Company Healthcare Health Diagnostics Biotechnology Life Sciences Cancer Screening Liquid Biopsy Laboratory

Kin Score

Kin Score How this is scored →
scored 2026-09-01 · rubric v0.17.2

Composite quality — 2.9/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 3.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 3/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Surface 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/mercy-bioanalytics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: mercy-bioanalytics
name: Mercy BioAnalytics
description: 'Mercy BioAnalytics, Inc. is a Waltham, Massachusetts clinical-stage cancer diagnostics company, founded in 2018,
  developing extracellular-vesicle (EV) based liquid biopsy tests for the early detection of cancer. Its patented Mercy Halo
  platform uses biomarker co-localization — the simultaneous detection of multiple cancer-related biomarkers on the surface
  of individual tumor-derived extracellular vesicles — to read a small volume of serum or plasma with a simple PCR-based readout.
  The company''s initial programs target ovarian cancer screening in asymptomatic post-menopausal women and lung cancer detection
  in average and high-risk individuals; the Mercy Halo Ovarian Cancer Screening Test received FDA Breakthrough Device Designation
  in May 2024. Mercy BioAnalytics raised a $41M Series A in April 2023 led by Novalis LifeSciences and a $59M Series B in
  September 2025. The product is a laboratory-developed blood test, not software: as of this profile the company publishes
  no public developer program, API, SDK, or machine-readable API contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/mercy-bioanalytics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-2026-08-25
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.20'
created: '2026-08-25'
modified: '2026-08-25'
tags:
- Company
- Healthcare
- Health
- Diagnostics
- Biotechnology
- Life Sciences
- Cancer Screening
- Liquid Biopsy
- Laboratory
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/mercy-bioanalytics-domain-security.yml
- type: Website
  url: https://mercybio.com/
- type: Support
  url: https://mercybio.com/contact/
- type: PrivacyPolicy
  url: https://mercybio.com/privacy-policy/
x-enrichment:
  date: '2026-08-25'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Mercy BioAnalytics sells a lab-run blood test (the Mercy Halo extracellular-vesicle liquid biopsy), not software
    — no api/developer/docs/portal/app subdomain of mercybio.com resolves in DNS, no GitHub org exists under mercybio or mercy-bioanalytics,
    no package is published to npm or PyPI, and every /openapi, /graphql and /.well-known path on mercybio.com is answered
    by a 169-byte SiteGround `sg-captcha` interstitial (HTTP 202) rather than a document.
  evidence:
  - url: https://mercybio.com/openapi.json
    status: 202
  - url: https://mercybio.com/.well-known/api-catalog
    status: 202
  - url: https://mercybio.com/.well-known/agent-card.json
    status: 202
  - url: https://api.github.com/orgs/mercybio
    status: 404
  checked: '2026-08-25'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools →

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/mercy-bioanalytics"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/mercy-bioanalytics/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/mercy-bioanalytics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.